Concepedia

Daniel Cloutier

DC

10

Publications

634

Citations

10

H-Index

2001

Active since

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

VIR Biotechnology (United States)

Justus-Liebig-Universität Gießen

Université Laval

Merck & Co., Inc., Rahway, NJ, USA (United States)

Daniel Cloutier is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, bacterial resistance, and clinical microbiology.

Top concepts

Publications per year

2001–2023

10

Publications

10

Once-Daily Plazomicin for Complicated Urinary Tract Infections

Florian Wagenlehner, Daniel Cloutier, Allison Komirenko et al. · New England Journal of Medicine · 2019 · 205 citations

, , +12

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials

Myra W. Popejoy, David L. Paterson, Daniel Cloutier et al. · Journal of Antimicrobial Chemotherapy · 2016 · 115 citations · Full text

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials

Ed Gane, Young‐Suk Lim, Jae Bum Kim et al. · Journal of Hepatology · 2023 · 89 citations · Full text

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Jennifer A. Huntington, George Sakoulas, Obiamiwe Umeh et al. · Journal of Antimicrobial Chemotherapy · 2016 · 59 citations · Full text

Recurrent sternal infection following treatment with negative pressure wound therapy and titanium transverse plate fixation☆

Geneviève Gaudreau, Victor Costache, Chanel Houde et al. · European Journal of Cardio-Thoracic Surgery · 2009 · 43 citations

Rows per page

1–5 of 10